|
|
Article: Medistem Laboratories Announces Beacon Equity Research Initiates Coverage of Medistem with Target Share Price of $1.20 and 'Speculative Buy' Rating; Report Cites Medical Promise of Medistem's Non-Controversial Adult Stem Cell Technology.
- Article from:
- Business Wire
- Article date:
- March 10, 2006
CopyrightCOPYRIGHT 2006 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SCOTTSDALE, Ariz. -- Medistem Laboratories, Inc. (OTCBB:MDSM)(FWB:S2U), committed to the ethical development of next-generation medical therapies from non-controversial adult stem cell sources, has announced that fee-based investment research firm Beacon Equity Research has rated Medistem as a "Speculative Buy," and has targeted the Company's 12-month share price at $1.20.
The report provides an overview of Medistem's strategic business initiatives, proprietary technologies and competitive advantages as it seeks to develop new stem cell-based therapies for a range of medical conditions. Among the competitive advantages noted in the report is Medistem's focus on ...